Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Buspirone PK and CYP3A4 Activity After RYGB
NCT02483598Phase 4
Key facts
- Status
- Terminated
- Start
- Jun 2015
- Primary completion
- Jun 2018
- Sponsor
- North Dakota State University
- Modality
- Small Molecules
- Drugs
- buspirone
- Conditions
- anxiety disorder
01
Overview
Phase 4, open-label trial of buspirone in anxiety disorder, sponsored by North Dakota State University. Primary endpoint: Area-under-the-curve. Started Jun 2015; status: terminated.
02
Design
- Study design
- Non-randomizedOpen-label
03
Who it enrols
Adults aged 18-65 who either underwent Roux-en-Y Gastric Bypass 9-18 months prior or are matched controls. Participants must be willing to consume grapefruit juice and have no contraindications to buspirone.
04
Endpoints
Primary
Area-under-the-curve
Secondary
Composite of pharmacokinetic measures
GLP-2 levels
Beyond the preview
Go deeper on NCT02483598.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02483598.